



EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

February 27, 2024

WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that Company management will participate at the following upcoming conferences:

- **TD Cowen 44th Annual Healthcare Conference**

Forum: Fireside Chat
Date: Tuesday, March 5, 2024
Time: 10:30 a.m. ET

- **Leerink Partners Global Biopharma Conference**

Forum: 1x1 Investor Meetings
Date: Monday, March 11, 2024

- **Guggenheim 5th Annual Healthy Altitudes Summit**

Forum: Fireside Chat
Date: Wednesday, March 13, 2024
Time: 9:15 a.m. ET

A webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, EYP-1901, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Beta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com



Source: EyePoint Pharmaceuticals, Inc.